XBIT
XBiotech Inc.
Healthcare — Biotechnology
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
None
$2.20
+$0.01 (+0.46%)
Price History
52-Week Range
Sign in to add XBIT to a watchlist or set price alerts.
Fundamentals
| Market Cap | $70.43M |
| P/E Ratio (TTM) | - |
| Forward P/E | 17.77 |
| EPS (TTM) | $-1.31 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -25.93% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 44.4 |
| Beta | 0.84 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $3.61 |
| 52-Week Low | $2.09 |
| 50-Day Avg | $2.43 |
| 200-Day Avg | $2.45 |
| Avg Volume | 27.9K |
| Volume | 316 |
Performance Analysis
NEUTRALXBIT presents a mixed picture with both positive and negative indicators.
+
Trading near its 52-week low ($2.09), which could present a value opportunity.
~
RSI at 44.4 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:38 UTC
Back to Screener Export Report